Dactinomycin Other names: Actinomycin D Actinomycin C1
Chemical formula: C₆₂H₈₆N₁₂O₁₆ Molecular mass: 1,255.417 g/mol PubChem compound: 457193
Active ingredient description
Dactinomycin is an antineoplastic antibiotic derived from Streptomyces parvullus. Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited. Protein and DNA synthesis are inhibited to a lesser extent.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| L01DA01 | Dactinomycin | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DA Actinomycines |
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| COSMEGEN Lyophilised powder for solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Medicines
Dactinomycin is an active ingredient of these brands:
Canada (CA)Estonia (EE)France (FR)Japan (JP)Lithuania (LT)Malta (MT)New Zealand (NZ)Romania (RO)United Kingdom (UK)United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.